Using an antiserum raised against defatted human cream, Heyderman et al. (1979) have identified a material which is localised on the luminal and surface membranes of most non-squamous tissues in humans. In normal tissues, this material, which they called epithelial membrane antigen (EMA), is not found on adjacent cell membranes but only on that part of the cell surface which is topographically part of the exterior surface of the body . Its widespread distribution suggests that EMA has an important role and, although this has yet to be defined, we have hypothesised that it has a protective function (Sloane et al., 1982) .
The production of EMA is increased in both squamous and non-squamous epithelium in a variety of diseases including many neoplasms. An immunohistochemical stain for EMA has considerable value in certain aspects of cancer research. It can be used in diagnostic tumour histopathology and cytology as an indicator of epithelial differentiation To et al., 1981 To et al., , 1982 and can be used, for example, to distinguish lymphoma from anaplastic carcinoma.
A stain for EMA has been used in the routine histopathology laboratory of the Surrey Branch of the Royal Marsden Hospital for over 2 years. A recent review of the results obtained showed that it was able to assist in a diagnosis of carcinoma in 22/48 problem cases ).
In the ectocervix, EMA is absent from normal squamous cells but is expressed if the epithelium is disordered in cases of infection, neoplasia and invasive carcinoma (Sloane et al., 1982; Bamford et al., 1983) . Antisera to EMA can be used to distinguish abnormal cells in smears made from cervical scrapes (Moncrieff et al., submitted for publication).
An immunohistochemical stain for EMA can identify minute metastatic deposits of carcinoma in organs such as liver and bone marrow (Sloane et al., 1980; Dearnaley et al., 1981) . Our most recent studies have shown that EMA positive cells can be found in the marrows of approximately one third of patients at the time of surgery for a primary breast cancer (Dearnaley et al., 1983) .
Because of its potential value in the detection and diagnosis of carcinoma, it is important to learn more of the chemical nature of this antigen. EMA is a component of the human milk fat globule membrane and is found in a soluble form in human milk. In this paper we describe methods for the purification of the antigen from this source and assays for its detection and quantitation, together with information on the chemical and physical properties of the antigen.
Materials and methods

Antisera
The anti-EMA sera were raised by the methods previously published (Ceriani et al., 1977; Heyderman et al., 1979) The affinity-column for preparing anti-EMA antibodies was made by linking purified EMA to the amino groups of 1, 6-diaminohexane-Sepharose (AH-Sepharose 4B; Pharmacia Ltd.) using 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide (Sigma Ltd.) and-following the instruction supplied by Pharmacia. The antibodies were eluted from the column using glycine-HCl, pH 2.3.
Column chromatography
The Sepharose 6B (Pharmacia Ltd.) columns (44x600mm) were run at 30mlh-1 and 0ml fractions were collected. The elution buffer was 0.1 M phosphate, 0.25 M NaCl, 1 mM EDTA, 3mMNaN3, 0.1% Triton X-l00, pH 8.0. They were calibrated using blue dextran, spleen ferritin (mol. wt=440 K daltons), IgG (150 K daltons), bovine serum albumin (67 K daltons) and cytochrome C (12.5 K daltons).
The (Heyderman et al., 1979) , we used this to detect EMA at the start of the purification.
When a crude preparation of EMA had been made, a radioimmunoassay was established. This was used to improve the purification procedure and to prepare EMA which was used in the radioimmunoassay described below.
Skimmed human milk was fractionated with (NH4)2 S04 and material of mol. wt > 106 was collected from a column of Sepharose 6B as described below. After extraction with chloroform-methanol (6 parts chloroform: 3 parts methanol: 1 part aqueous solution), the EMA activity was recovered in the aqueous phase. This material was dialysed and used in the assay.
The solution of EMA was diluted in carbonate buffer, pH 9.6, and 50u1 added to small polystyrene wells (Removawell, Dynatech Ltd). Thereafter all dilutions and washings used phosphate buffered saline (0.1 M phosphate, 0.15 M NaCl, 3 mM NaN3, pH 7.5), containing 1% bovine serum albumin. Twenty-five p1 of goat anti-EMA serum at a dilution of 1 in 100 was added in separate wells to 100 p1 of each test fraction diluted as appropriate. After incubation at ambient temperature overnight, the Removawells were washed thoroughly and 50MI
of the antiserum-test sample mix was added. After 2 h at ambient temperature, the wells were washed, incubated with 125I-labelled anti-goat y-globulins (0.2pCi per well) for 1h, washed and counted. A particular sample of milk was set aside for use as a standard for this assay. In later work a purified sample of EMA has been used as a standard. Typical curves obtained by this procedure are shown in Figure 1 . The data given in the rest of this paper were obtained using this assay.
Any impurity in the EMA preparation to which there was an an antibody in the antiserum would interfere in the assay. To check this, the purer preparations of EMA were used to afflnity-purify goat antibodies (see Materials and methods) and a radioimmunometric assay was established. Gamma globulins from a rabbit antiserum were absorbed to the Removawells by incubation at pH 9.6. After washing, dilutions of either purified EMA or of the test sample were added to the wells and left overnight. After further washing, the wells were incubated with affinity-purified goat antibodies, washed and finally incubated with 125I-rabbit antigoat antibodies. Using this alternative assay, the purification procedure was re-checked. No significant difference was found in the results using the two assays. Table I shows the results obtained during a typical preparation of EMA.
Purification procedures
Human milk (11), pooled from different donors and after removal of the cream, was brought to 40% saturation with (NH4)2SO4 and the precipitate removed by centrifugation. The supernatant (which contained 75% of the EMA activity) was brought to 80% saturation with (NH4)2SO4, the precipitate collected, dissolved and dialysed against distilled water, concentrated and made 1% in the detergent Triton X-100. This material was divided into four and each part fractionated on a column of Sepharose 6B, 0.1% Triton X-100, pH 8.0. The active fractions which eluted in a position corresponding to a mol. wt > 106 ( Figure 2 ) were bulked, concentrated and then stirred with 6 vol of chloroform and 3 of methanol. After separation, the organic phase and the precipitated proteins at the interface were discarded . The aqueous phase 'Determined using the Bio-Rad assay. 2Determined using the radioimmunoassay described in this paper. 3This value is calculated assuming that the final purification stage gives pure EMA. affinity purification on peanut lectin since material obtained from the ion exchange column before further purification on the peanut lectin also contained large quantities of galactose as did a sample which was affinity purified on immobilised goat anti-EMA antibodies. N-acetyl-glucosamine is also a major sugar in all of the preparations. Other sugars are present in the antigen in more variable quantities.
When one of the samples of EMA (EMA Dl) was treated in sequence with periodate, borohydride and dilute acid (i.e. degraded according to the procedure of Smith (Hay et al., 1965) ) a considerable simplification of monosaccharide composition of the antigen was achieved (Table III) with no apparent loss in antigenic activity of the antigen (Figure 4) . N-acetyl-glucosamine, galactose and N-acetyl-galactosamine were the only significant remaining sugars and were present in the simple molecular ratio of 2: 1: 1.
Amino acid analyses of the protein portion showed considerable variation. A consistent feature was the absence of tyrosine which accords with the difficulty encountered in attempting to label the antigen with 125I. ( Figure 5 ). The activity of EMA was unaffected by placing a solution in a boiling water bath for 2min. It was also unaffected by heating to 90°C for 2 min in the presence of 3% SDS and 1% mercaptoethanol. On a polyacrylamide gel at pH 8.6 the EMA activity had a low electrophoretic mobility in the presence or absence of SDS. Figure 6 shows a comparison of EMA activities in skimmed milk and a preparation of EMA. The latter had a wide range of mobilities consistent with a larger spread of mol. wt.
Treatment with trypsin (1 mg per 10mg protein) for 17 h at 37OC had no effect on the EMA activity.
Treatment wiLn pronase (1 mg per 10mg protein) for 2 h at 37°C also had no effect but if the incubation was extended to 17 h, there was a lowering of activity. This is an excessive length of treatment for this enzyme and the effect could have been due to trace impurities in the pronase sample and not its proteolytic activity. EMA could be exposed for up to 4 h to either 1 M acetic acid or 6 M guanidine without effect but exposure for 18 h or more did lead to loss of activity. If exposure to either acetic acid or guanidine is not excessive, then columns in either of these reagents can give a considerable purification of EMA at an early stage in the procedure. However, these columns removed little that was not removed by extraction with chloroform/methanol.
As The discovery of EMA in a soluble form in human milk presented an opportunity to purify the antigen and thereby to examine the structure of the molecules. As our attempts at purification proceeded, it became clear that the antigenic determinants were not carried on one well-defined molecule but that we were dealing with a heterogeneous set. This is evident from the spread of apparent mol. wt on the Sepharose column. EMA is present in the membrane of the milk fat globules which have arisen from the apical membranes of the secretory cells of the breast and the soluble antigen is probably formed by degradation of milk fat globule membranes in the milk. This degradative process might explain the variability in the protein content. The variation from one preparation to another was far higher than would be expected even taking into consideration the low protein content of the final product. Batches of milk from different women might vary appreciably in the extent to which the antigen had been degraded. An alternative explanation for the variability in protein is that much of this material is impure. This seems unlikely since on SDS-polyacrylamide gels the only protein band observed (and that was very weak) co-eluted with the EMA activity as measured by the radioimmunoassay. We have found previously that such gels would separate EMA from casein with which the antigen had been co-purified Two other perplexing features of the purification were our inability to account for all of the material present and the high ash content. With different samples we could account for between 45 and 80% of the total wt in terms of carbohydrate, protein and inorganic material. It is unlikely that much lipid is present as a lipid would be expected to partition into the organic phase during the chloroform-methanol extraction. The ash present was not phosphate or sulphate. Whatever its composition, it was firmly bound to the sample since the EMA had been affinity purified on peanut lectin after it had last been dissolved in a buffer. Thereafter it was handled in distilled water.
While the protein content of the preparations of EMA was low, carbohydrate constituted the major identified part of the preparations with galactose and N-acetyl-glucosamine being the predominant sugars; five other sugars, however, were also identified.
Smith degradation considerably simplified the carbohydrate composition leaving Nacetyl-glucosamine, galactose and N-acetylgalactosamine, in the molecular ratio of 2: 1: 1, respectively; the modified antigen retained its antigenic activity. This may mean that the major antigenic determinants contain a combination of these sugars particularly as removal of the majority of the sugars from the antigen using neuraminidase and a mixture of glycosidases isolated from Trichomonas foetus (Watkins, 1966) caused a large reduction in antigenic activity (unpublished results) whereas treatment of EMA with trypsin caused little loss in EMA activity. Although the Smith degradation of EMA would be expected to destroy carbohydrate determinants, it may also expose cryptic carbohydrate structures similar to the ones which originally bound to the antiserum.
Recently, Shimizu & Yamuchi (1982) have extracted a mucin-like glycoprotein from the human milk fat globule membrane using a mixture of deoxycholate, urea and mercaptoethanol. This glycoprotein has many properties similar to EMA but it will only be possible to confirm the identity of the two materials by comparing them in a radioimmunoassay.
It is clear from our results that our polyclonal antisera, while identifying a ubiquitous structure associated with epithelial differentiation and of practical importance in cancer research, are not reacting with a simple molecular species. We have probably isolated a set of products resulting from the breakdown of a much larger component of the membrane. We present the purification method developed now because it produces a product which can be used to absorb antisera (an important control in immunohistochemical work), it forms the basis of our radioimmunoassay which can be used to detect EMA released in the plasma of patients with breast cancer (Ormerod et al., in preparation) , and it gives the starting material for more detailed work on the structure of the antigenic determinants. This will be achieved by a variety of methods including selective degradation of the carbohydrate structure. There are now, in addition to the polyclonal antisera used for the work described in this paper, 5 monoclonal antibodies available, one raised in the Ludwig Institute for
